Get the latest news, insights, and market updates on RPRX (Royalty Pharma plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
PTC Therapeutics Q4 Earnings Call Highlights
PTC Therapeutics (NASDAQ:PTCT) reported fourth-quarter and full-year 2025 results highlighted by the initial global approvals and early launch performance of Sephience for phenylketonuria (PKU), which management described as the company’s “foundational product” for near-term growth. 2025 results an Feb 20, 2026 - $RPRX
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 10.8% over the past six months, topping the S&P 500 by 4.1 percentage points. Feb 19, 2026 - $RPRX
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) beat Wall Street’s revenue expectations in Q4 CY2025 as sales rose to $874 million.Correction note:The previous version of this report had incorrect analysts' sales and EPS estimates. This has been updated in the current version. CEO Pablo Legorreta pointed to the diversification and resilience of the portfolio as a mitigating factor, emphasizing that “conversion of CF patients to new therapies has been steady but gradual.” Management als Feb 18, 2026 - $RPRX
Vertex Pharmaceuticals Q4 Earnings Call Highlights
Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF), Feb 13, 2026 - $RPRX
Royalty Pharma Q4 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) executives highlighted what they described as a “landmark year” in 2025, pointing to double-digit top-line growth, continued capital deployment into new royalty deals, and a significant strategic change with the internalization of the company’s external manager. Manageme Feb 11, 2026 - $RPRX
Royalty Pharma Reports Q4 and Full Year 2025 Results
Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced f Feb 11, 2026 - $RPRX
Royalty Pharma: Q4 Earnings Snapshot
NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported fourth-quarter net income of $214 million. The New York-based company said it had net income of 38 cents per share. Earnings, adjusted for non-recurring costs, came to $1.46 per share. Feb 11, 2026 - $RPRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple